NOW ENROLLING: New Global Study Investigates Medication Designed to Treat Early-Stage Parkinson’s

A new study testing CoganeTM (PYM50028) - a medication designed to treat early-stage Parkinson’s disease – just moved into Phase II clinical trials. United Kingdom researchers are currently recruiting 400 participants worldwide.

Eligible participants are men and women between ages 35 and 75 with a diagnosis of Parkinson’s within the last two years. The research will study whether Cogane could slow down or modify the progression of Parkinson’s. Cogane is a new compound that modulates proteins in the brain that help the survival, development and function of nerve cells.

For more information, see Clinical Trials: Studies Seeking Participants.

http://ping.fm/rQWPp